No. 19-1073

Enzo Life Sciences, Inc. v. Roche Molecular Systems, Inc., et al.

Lower Court: Federal Circuit
Docketed: 2020-03-02
Status: Denied
Type: Paid
Response Waived
Tags: 35-usc-112 35-usc-282 clear-and-convincing-standard enablement inoperability non-enabled-claims patent-law patent-validity presumption-of-validity statutory-interpretation unpredictability
Key Terms:
Patent
Latest Conference: 2020-03-27
Question Presented (AI Summary)

Whether patent claims that cover a class may be invalidated as non-enabled under 35 U.S.C. § 112 based on a finding of high unpredictability in the art despite an absence of any evidence of inoperability within the class

Question Presented (OCR Extract)

QUESTIONS PRESENTED I. In light of a patent’s presumption of validity under 35 U.S.C. § 282 and the concomitant clear and convincing standard for proving invalidity, may patent claims that cover a class be invalidated as non-enabled under 35 U.S.C. § 112 based on a finding of high unpredictability in the art despite an absence of any evidence of inoperability within the class? II. In concluding that the patent claims that cover a class are invalid as non-enabled under 35 U.S.C. § 112 despite an absence of any evidence of inoperability within the class, did the United States Court of Appeals for the Federal Circuit (“Federal Circuit”) erroneously shift the burden to the patent owner to prove the claims were enabled, and therefore valid, in violation of the presumption of validity under 35 U.S.C. § 282? i

Docket Entries

2020-03-30
Petition DENIED. Justice Alito took no part in the consideration or decision of this petition.
2020-03-11
DISTRIBUTED for Conference of 3/27/2020.
2020-03-02
Waiver of right of respondents Abbott Laboratories; Abbott Molecular, Inc. to respond filed.
2020-03-02
Waiver of right of respondents Roche Molecular Systems, Inc.; Roche Diagnostics Corporation; Roche Diagnostics Operations, Inc.; Roche Nimblegen, Inc.; Becton, Dickinson and Company; Becton Dickinson Diagnostics Inc.; and Geneohm Sciences Inc. to respond filed.
2020-02-26
Petition for a writ of certiorari filed. (Response due April 1, 2020)
2020-01-17
Application (19A800) granted by The Chief Justice extending the time to file until February 26, 2020.
2020-01-14
Application (19A800) to extend the time to file a petition for a writ of certiorari from January 27, 2020 to February 26, 2020, submitted to The Chief Justice.

Attorneys

Abbott Laboratories; Abbott Molecular, Inc.
John Caviness O'QuinnKirkland & Ellis LLP, Respondent
John Caviness O'QuinnKirkland & Ellis LLP, Respondent
Enzo Life Sciences, Inc
Justin Patrick Daniel WilcoxDesmarais LLP, Petitioner
Justin Patrick Daniel WilcoxDesmarais LLP, Petitioner
Roche Molecular Systems, Inc.; Roche Diagnostics Corporation; Roche Diagnostics Operations, Inc.; Roche Nimblegen, Inc.; Becton, Dickinson and Company; Becton Dickinson Diagnostics Inc.; and Geneohm Sciences Inc.
Thomas Glenn SaundersWilmer Cutler Pickering Hale and Dorr LLP, Respondent
Thomas Glenn SaundersWilmer Cutler Pickering Hale and Dorr LLP, Respondent